ArticleDEN open2026
Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and Safety of Balloon Endoscopy-Assisted Peroral Cholangiopancreatoscopy (POCPS) Using a Novel 9Fr Cholangioscope in Patients With Surgically Altered Anatomy: A Dual-Center Retrospective Study (With Video).Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- Feasibility of Peroral Pancreatoscopy Using the 9-Fr eyeMAX for Surgical Planning in Main-Duct and Mixed-Type Intraductal Papillary Mucinous Neoplasms.Diagnostics (Basel, Switzerland) · 2026Article
- Advances in Diagnosis and Treatment With Cholangiopancreatoscopy.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Review
- A novel slim cholangioscope facilitates antegrade laser lithotripsy for an intrahepatic biliary stone with acute ductal angulation.Endoscopy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the clinical outcomes of peroral cholangiopancreatoscopy (POCPS) using the 9-Fr eyeMAX for the diagnosis of pancreatobiliary diseases. Methods: This retrospective study enrolled 43 patients who underwent POCPS using the 9-Fr eyeMAX for diagnostic procedures at two tertiary referral centers between May 2023 and November 2024. The primary outcome was the incidence of adverse events following POCPS. Patient backgrounds, procedural details, technical success (successful insertion of the 9-Fr eyeMAX), and adequate tissue sampling were also analyzed. Results: Of the 43 patients, 32 were male, and 11 were female, with a median age of 75 years (range, 46-87 years). Peroral cholangioscopy (POCS) was performed on 30 patients. The final diagnosis in this cohort was an ampullary tumor ( Conclusions: The 9-Fr eyeMAX facilitates a safe POCPS procedure, achieving a high technical success rate and an adequate tissue sampling rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.